Can an antifungal pill ease inflammatory bowel disease?
In one group of patients, yes. Among 53 people with mild-to-moderate ulcerative colitis or Crohn’s disease who also had mild oral thrush, only the antifungal pill fluconazole lowered the amount of Candida yeast in the gut, and those patients had better disease activity scores over the next 8 weeks. The patients who used an antifungal mouthwash instead did not see the same changes.
This was not a drug trial. It was a prospective observational study, called IVAN, at Weill Cornell Medicine. It enrolled patients with IBD who had mild oral thrush, a fungal infection of the mouth. Thrush gets treated anyway, so the researchers watched what happened to the gut when it was treated two different ways.
Eighteen patients got nystatin, a swish-and-spit mouthwash that kills yeast in the mouth and then gets spat out. Thirty-five got fluconazole, a pill that travels through the bloodstream and reaches the intestines. Both treatments ran for two weeks and both cleared the thrush. Only one of them changed anything downstream.
Why gut fungi matter in inflammatory bowel disease
Most microbiome talk is about bacteria. Fungi live down there too, in much smaller numbers, and they are far less studied. Dr. Iliyan Iliev’s lab at Weill Cornell has spent more than a decade on them. Their earlier work showed that some strains of the yeast Candida albicans make a toxin called candidalysin, which damages the cells lining the intestine and sets off an inflammatory immune response.
The study needed a way to pick out patients whose fungi were worth targeting. The researchers found that genetically related Candida strains were often shared between a patient’s mouth and their gut. That means a cheek swab can stand in for what is happening in the intestine, which is what made this study design possible in the first place.
What the data show
Fluconazole reduced the Candida burden in the intestine and reshaped the fungal community there. Nystatin did not, which makes sense given it never leaves the mouth.
What followed the fluconazole was a broader change. Bacterial diversity went up. Bacteria that produce short-chain fatty acids expanded, including the ones that make butyrate, a fuel source for the cells lining the colon. Anti-inflammatory microbial metabolites, the useful chemical byproducts of a healthy gut community, came back. The shifts in how bacteria and fungi related to each other lasted for weeks after the two-week course ended. Those microbiome changes lined up with improved disease activity scores and a lower probability of disease progression across the 8-week follow-up.
Dr. Kumar’s Take
The design is cleverer than it first looks. These patients were going to be treated for thrush regardless, and the two treatments differ in exactly one useful way: whether the drug reaches the gut. That gives you something close to a natural comparison without giving anyone a drug they did not need.
The caveats are real and the authors say so themselves. The study was not randomized, had no placebo group, and was not designed to prove that fluconazole treats IBD. The two groups were not the same size, patients and doctors knew which treatment they got, and 8 weeks is a short window in a disease measured in decades. Disease activity scores also move on their own.
Fluconazole is not a casual drug either. It interacts with a long list of common medications and it is processed by the liver, so it is not something to add to an IBD regimen on a hunch. What this study earns is a proper trial, not a prescription.
Who this might apply to
Not every IBD patient has a fungal problem. This study deliberately selected people who had visible evidence of one, in the form of oral thrush. That selection is the point: the researchers are arguing for stratification, meaning you test first and treat only the patients whose biology says they might respond.
The open question is whether patients without thrush but with a positive cheek swab for Candida would benefit the same way. The team plans to look at that, along with a larger multicenter placebo-controlled trial to confirm whether the improvement in symptoms holds up when you remove the ways a study like this can fool you.
Practical Takeaways
- If you have IBD and you also get recurring oral thrush, mention it to your gastroenterologist, since the fungal side of the microbiome is now something worth tracking rather than treating as an unrelated nuisance.
- Do not ask for fluconazole as an IBD treatment on the strength of this study, because it was not designed to test that and the drug interacts with many common medications.
- Keep taking your prescribed IBD therapy, since this study followed an antifungal given for oral thrush and never tested it as a replacement for IBD treatment.
- Watch for the larger randomized trial the researchers have planned, which is what will settle whether the symptom improvement was really caused by the antifungal.
Related Studies and Research
- Time-restricted feeding improves Crohn’s disease activity in a new trial
- Time-restricted feeding cut Crohn’s disease activity in a 12-week trial
- A plant-based diet lowered heart disease risk over 20 years
- Does exercise lower dementia risk? Only in your free time
FAQs
Does everyone with Crohn’s or colitis have too much Candida in their gut?
No. Fungal overgrowth appears to be a feature of some patients, not all of them, which is why this study screened for it rather than assuming it. Every participant here had mild oral thrush, a visible sign of Candida overgrowth, and that was the entry ticket. The researchers found that the Candida strains in a patient’s mouth were often genetically related to the ones in their gut, which is what makes a cheek swab a plausible screening tool. Whether the same benefit shows up in patients who carry gut Candida without ever developing thrush is still unknown.
Why did the mouthwash not work if it also killed the yeast?
Nystatin is swished and spat, so it acts locally in the mouth and essentially never reaches the intestine. It cleared the oral thrush just as well as the pill did, which is a useful detail: both groups got the same visible result in the mouth, and only the group whose drug traveled to the gut saw changes in the intestinal fungal and bacterial communities. That contrast is the strongest part of the study, because it points to the gut, not the mouth, as the place where the improvement came from.
What is butyrate and why does it matter in inflammatory bowel disease?
Butyrate is a short-chain fatty acid that gut bacteria produce when they ferment fiber. It is the main fuel for the cells lining the colon, and it helps keep the gut barrier intact and inflammation in check. In this study, fluconazole treatment was followed by an expansion of the bacteria that produce short-chain fatty acids, along with a return of anti-inflammatory microbial metabolites. That is the proposed chain of events: fewer fungi, more helpful bacteria, more of the compounds that calm the gut lining.
Bottom Line
In 53 patients with mild-to-moderate IBD and oral thrush, a two-week course of fluconazole lowered gut Candida, increased bacterial diversity, restored short-chain fatty-acid producers and anti-inflammatory metabolites, and tracked with better disease activity and a lower chance of disease progression over 8 weeks. A nystatin mouthwash, which never reaches the gut, did none of that. This is the first human evidence that targeting gut fungi can remodel the wider microbiome in IBD, and it is an observational study in a selected group of patients, so the next step is a randomized placebo-controlled trial rather than a change in practice.
